Ann: Final Phase IIb AIPAC clinical trial results for Efti in MBC, page-102

I think its becoming obvious that Efti is a mega blockbuster drug that will likely benefit a large number of cancer treatments involving chemo and immunotherapy.
It will likely become a universal SOC, and imo, the highest revenue generating cancer treatment for many decades.
To get to the above, we will need a phase3 and approval, which is why they will pursue AIPAC which is the shortest route. It will be interesting to see if they do a deal or go it alone.
In any case, things are going to heat up. Don’t get shaken out.